Neil Jenkins is a partner in the London IP litigation practice group and the international life sciences sector group. He joined the firm in 1986 and became a partner in 1996.
Neil has particular interest and expertise in the management and conduct of cross border patent litigation. His practice is focused on patent, trademark, copyright, design and trade secret litigation. It also encompasses such associated matters as regulatory data exclusivity, supplementary protection certificates, labelling and advertising as well as domain name disputes, brand management and anti-counterfeiting.
His more high profile cases, before the English Courts and in the CFI include PLG v Ardon (plastic grids), ICI v Montedison (polymer composite), HCC v BP (acetic acid purification), UCC v BP (fluid bed production of polyethylene), Stephenson v Du Pont (entitlement), Hesco v Maccaferri (gabions), Chef Revival v OHIM (Chef mark), Agilent v Waters (HPLC pumps), Teva v Merck (alendronate), Teva v Merck (simvastatin), Lundbeck v Niche (citalopram), Abbott v APS (clarithromycin), Celltech v OHIM (Celltech mark), Actavis v Merck (finasteride), Actavis v Novartis (fluvastatin), Specialty Brands v OHIM (Dog Device), Teva v Merck (timolol/dorzolamide combination) and Generics v Yeda/Teva (Copaxone).
Neil speaks regularly at IP conferences and contributes to the leading IP journals on many aspects of IP law and litigation as well as being the editor of International Intellectual Property Litigation (published by Butterworths). He is a member of the IPO international patent law and practice committee, the INTA publications sub-committee and the CIPA litigation sub-committee.
Who's Who Legal 2012 commented that Neil is 'at the top of his game' while Chambers UK 2013 noted that 'Interviewees praise Neil Jenkins for his 'sound, common-sense' approach to IP matters.'
This biography is an extract from The International Who's Who of Life Sciences Lawyers which can be purchased from our Shop.
Neil Jenkins also features in the following practice areas:
It is not possible to buy entry into any Who's Who Legal publication
Nominees have been selected based upon comprehensive, independent survey work with both general counsel and private practice lawyers worldwide. Only specialists who have met independent international research criteria are listed.